IADVL 关于印度毛癣菌感染的共识建议:改良德尔菲法
印度皮肤病、性病与麻风病医师协会组建14名皮肤科医生、2名真菌学家和1名药理学家的小组,基于2017年以来文献用改良德尔菲法制订印度毛癣菌感染的定义、诊断与治疗共识。核心推荐伊曲康唑为一线系统用药、高剂量特比萘芬为二线,4周反应不佳即换药并持续治疗至痊愈。
要点
- 伊曲康唑为一线系统抗真菌药,高剂量特比萘芬为二线。
- 4周疗效不佳即更换系统抗真菌药,疗程持续至痊愈。
- 复发者采用与初治相同的方案治疗。
核心结论
- 小组就印度毛癣菌感染的临床与诊断方面提出建议,旨在改善患者结局并促进学术交流与研究。
研究设计与样本
- 由IADVL组建的14名皮肤科医生、2名真菌学家和1名药理学家小组,分析2017年以来相关文献,采用改良德尔菲法,未达75%共识的领域以修改后问题重复征询,最多三轮。
- 疾病定义由临床专家讨论达成,真菌学(诊断)指南由真菌学专家成员通过互相同行评审各自草案制定。
- 共向14名皮肤科医生提出87个治疗相关问题。
主要发现
- 提出了供临床与研究使用的疾病定义。
- 临床 doubtful 病例推荐KOH涂片检查,培养、抗真菌药敏试验和测序推荐在专业真菌学实验室用于监测流行菌种趋势和药物敏感性。
关键数值与推荐
- 推荐伊曲康唑(ITZ)作为一线系统用药,特比萘芬(TRB)(更高剂量)作为二线。
- 4周应答不充分时更换系统抗真菌药。
- 采用延长治疗(直至痊愈),复发以与初始治疗相同的方案治疗。
- 提供了治疗监测及特殊场景(儿童、妊娠、哺乳、肾功能或肝功能不全、心力衰竭、使用外用/系统激素或免疫抑制剂者)的治疗建议。
临床怎么用
- 对临床疑似印度毛癣菌感染可按共识定义识别, doubtful 病例行KOH涂片,疑难或监测需求转专业真菌学实验室做培养、药敏和测序。
- 系统治疗首选伊曲康唑,二线选高剂量特比萘芬,4周评估疗效并及时换药,坚持治疗至痊愈,复发沿用原方案。
- 特殊人群(妊娠、哺乳、肝肾功能不全、心衰、使用激素或免疫抑制剂者)按共识对应建议处理。
局限性
- 共识基于改良德尔菲法和专家意见,原文摘要未报告具体证据等级、样本量或统计学数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trichophyton indotineae has emerged as a significant novel species causing tinea corporis/cruris/faciei, with established endemicity in a few regions and potential for expanding endemic zones in future. OBJECTIVES: We aimed to develop consensus on disease definitions, diagnosis and treatment of T. indotineae infection. METHODS: Relevant literature from 2017 onwards was analysed and presented to the panel of dermatology experts, followed by circulation of a structured Google questionnaire encompassing various aspects of systemic and topical treatment, including special scenarios. Repeat rounds with modified questions were conducted in domains where (75%) consensus was not achieved, till a maximum of three rounds. Disease definitions were arrived at by discussion among clinical experts. Mycological (diagnostic) guidelines were formulated by the expert mycology members through peer review of each other's drafts. RESULTS: The panel comprised 14 dermatologists, 2 mycologists and 1 pharmacologist. Disease definitions for clinical and research use are presented. KOH smear testing is recommended in clinically doubtful cases, whereas culture, antifungal susceptibility testing and sequencing are recommended for monitoring trends of prevalent species and drug susceptibility in specialized mycology laboratories. A total of 87 therapeutic questions were put to the 14 dermatologists. Key therapeutic recommendations include the use of itraconazole (ITZ) as a first-line systemic agent and terbinafine (TRB) (higher dose) as a second line, switching systemic antifungal in case of inadequate response at 4 weeks, use of prolonged treatment (till cure) and treatment of relapses with the same regimen as used for initial treatment. Recommendations for treatment monitoring and treatment in special scenarios such as paediatric patients, pregnancy, lactation, renal or hepatic dysfunction, cardiac failure and patients on topical/systemic steroids or immunosuppressives are presented. CONCLUSIONS: The panel has made recommendations on clinical and diagnostic aspects of T. indotineae infections, which would improve patient outcomes and foster academic communication and research. A clinically relevant superficial fungus—Trichophyton indotineae, responsible for recurrent and difficult to treat skin infections, has been spreading globally over the past decade. There are, however, significant evidence gaps regarding its diagnosis and management. To address this, a panel constituted by the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL), consisting of 14 dermatologists, 2 mycologists, and 1 pharmacologist, reviewed current literature on the subject and prepared guidelines on diagnosis and treatment of T. indotineae infection. The panel recommends disease definitions that are of utility in clinical and research settings. Mycology experts have formulated recommendations on the diagnosis of the infection. Treatment guidelines were prepared following a modified Delphi consensus procedure wherein a total of 87 questions were put across to dermatologist members in two parts. Key treatment recommendations are to use itraconazole as the first‐line oral antifungal and high‐dose terbinafine as second‐line therapy, with a switch in antifungal at 4 weeks in case of suboptimal response, and continuation of treatment until complete cure. The same treatment is advised for relapses. Treatment for special scenarios such as pregnancy, lactation, coexistent kidney/liver/heart disease, etc., has been advised in accordance with existing evidence. KOH smear is recommended in clinically doubtful cases, while culture, antifungal susceptibility testing and sequencing are advised for accurate identification of the fungus and for surveillance purposes. The guidelines will help doctors worldwide in the diagnosis and treatment of skin infections caused by this fungus.
引用
- Khurana A, Jayaraman J, Adil M, et al. IADVL consensus recommendations on Trichophyton indotineae infections: Using modified Delphi method. J Eur Acad Dermatol Venereol. 2026. PMID: 42820589. doi:10.1111/jdv.70693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。